HT team
October 11, 2022: The Competition Commission of India, the country’s anti-trust regulator has given the nod for Platinum Owl to buy a minority stake in Intas Pharmaceuticals.
The proposed transaction involves a secondary acquisition by Platinum Owl of 3 percent of the equity shareholding of Intas (on an outstanding shares basis), according to a government statement.
Intas, an Indian public company based out of Gujarat, manufactures and markets pharmaceutical formulations and is the parent company of the Intas group.
The products of Intas have a pan-India presence and have an extensive portfolio of specialty and generic pharmaceuticals exported globally from its manufacturing facilities in India.
Accord Healthcare
Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. It is currently present in more than 85 countries.
Platinum Owl is a private limited company, incorporated in the Abu Dhabi Global Market (ADGM). Abu Dhabi Investment Authority is the sole beneficiary and settlor of the Platinum Jasmine A 2018 Trust.
The investment authority. is a public institution established as an independent investment institution by the Government of the Emirate of Abu Dhabi.
